Natural mouthwash aimed to soothe radiation mouth sores, but study never started

NCT ID NCT06708702

Terminated Symptom relief Sponsor: Instituto Nacional de Cancer, Brazil Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test a mouthwash made from copaíba oil, a natural resin, to prevent and treat painful mouth sores (oral mucositis) in people with oral cancer undergoing radiation. The trial was set to include 40 patients, half using the copaíba mouthwash and half a placebo, four times a day. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Copaíba oil (Copaifera Officinalis Resin) mouthwash
What this could lead to: If it had worked, this could have pointed toward a natural mouthwash to ease painful mouth sores during cancer treatment.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. Even if conducted, it was a small early-phase study with only 40 patients, so success was uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL CAVITY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced oral mucositis oral cavity cancer oropharynx cancer stomatitis ulcer disease ulcerative stomatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL MUCOSITIS ORAL MUCOSITIS (ULCERATIVE) DUE TO ANTINEOPLASTIC THERAPY ORAL MUCOSITIS (ULCERATIVE) DUE TO RADIATION ORAL MUCOSITIS DUE TO RADIATION

Contacts and locations

Locations

Instituto Nacional de Cancer

Rio de Janeiro, Rio de Janeiro, 20231050, Brazil
Instituto Nacional de Cancer, Brazil

Rio de Janeiro, Rio de Janeiro, 20231050, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.